A series of correspondences published in the Annals of Rheumatic Diseases discussed the role of corticosteroid modification in the treatment of patients with sarcoidosis who developed COVID-19 and later highlighted potential protective qualities of TNF-alpha antagonists. The gene discussed is TNF; the disease is COVID-19.